From March 15, 2023: Rick Outzen talks with attorney Troy Rafferty of Levin Papantonio Rafferty about the firm's class-action litigation against insulin manufacturers. Rafferty explains why Eli Lilly's 70% price cut is "too little too late," detailing how three pharmaceutical companies control 99% of the insulin market and have raised prices over 1,000% since 2003, despite the drug costing pennies to produce, forcing diabetic families to ration a life-saving medication.
Note: Rafferty has formed a new firm, Rafferty Domnick Cunningham & Yaffa. It and Levin Papantonio are involved in litigation regarding insulin price-fixing.